- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 5, 2022
Regulation
May 4 Quick Takes: FDA clears Fujirebio’s Alzheimer’s diagnostic
Plus Jazz licenses sleep disorder therapy from Sumitomo and updates from Apnimed, Phathom, AZ, Kezar
BioCentury | Nov 10, 2021
Product Development
Genentech pours cold water on blood test for Alzheimer’s screening
Argues plasma Aβ42/40 falls short as a method for identifying patients for clinical trials
BioCentury | Feb 15, 2019
Product R&D
A bug about Alzheimer’s
Cortexyme offers a new MOA in Alzheimer’s, faces down skeptics
BioCentury | Jan 25, 2019
Clinical News
Cortexyme's bacterial protease inhibitor improves AD signs in mice
BioCentury | Jan 24, 2019
Preclinical News
Cortexyme's bacterial protease inhibitor improves AD signs in mice
BioCentury | Nov 6, 2018
Finance
Advancing AlzeCure
AlzeCure plans to bring its Alzheimer’s programs to the clinic with $22M IPO
Items per page:
1 - 10 of 73